budiodarone

Small moleculeexperimental

Budiodarone (ATI-2042) is an antiarrhythmic agent and chemical analog of amiodarone that is currently being studied in clinical trials. Amiodarone is considered the most effective antiarrhythmic drug available, but its adverse side effects, including hepatic, pulmonary and thyroid toxicity as well as multiple drug interactions, are discouraging its use. Budiodarone only differs in structure from amiodarone through the presence of a sec-butyl acetate side chain at position 2 of the benzofuran moiety. This side chain allows for budiodarone to have a shorter half-life in the body than amiodarone which allows it to have a faster onset of action and metabolism while still maintaining similar electrophysiological activity. The faster metabolism of budiodarone allows for fewer adverse side effects than amiodarone principally due to decreased levels of toxicity in the body. — Wikipedia

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2006 (NCT00389792)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetOTHER

    Unknown

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)OC(=O)Cc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
Mol. weight
703.35 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • at1-2042
  • ati2042
  • ati 2042
  • ati-2042
  • ati-2042
  • ati-2042
  • ati-2042
  • budiodarone
  • budiodarone
  • budiodarone
  • budiodarone tartrate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00389792Phase 2Jul 1, 2006ARYx Therapeutics, Main Line Health
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ARYx TherapeuticsFor profit1112006
Main Line HealthAcademic/Hospital1012006
2 organizations
Page 1 / 1